Currently, multiple lines of evidence suggest that protein arginine methyltransferase 5 (PRMT5) and serine arginine protein kinase 1 (SAPK1) are potential therapeutic targets for PCa [40–42]. Here, MAPK8 is linked to posterior cortical atrophy.